AHNAK2 Urinary Protein Expression as Potential Biomarker for Bladder Cancer Detection: A Pilot Study
Open Access
- 1 November 2022
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 48 (6) , 423-430
Abstract
Objective: This study aimed to measure the AHNAK2 urinary levels in bladder cancer patients. Material and methods: This prospective case–control study enrolled 67 participants between January and March 2019 and were categorized into bladder cancer group (n=37), with histologically proven bladder cancer, and control group (n=30), with histologically verified benign lesions or with no bladder cancer indication during follow-up. Urine samples of 15 mL were collected in the mid-morning before cystoscopy/surger y and an enzyme-linked immunosorbent assay was performed as per the manufacturer’s protocol. Bladder malignancies were classified according to the World Health Organization Tumor Classification. Group’s associations were evaluated with the Student t-test, Spearman’s rank correlation, and Mann–Whitney U test, while receiver operating curve was plotted for assessing the test’s performance. Results: Mean age of the bladder cancer group was 66.41 years (standard deviation=10.04, range=43-82 years) and the control group was 59.67 years (standard deviation=10.44, range=38-77 years). All bladder cancers were of the urothelial histotype, with the following pT distribution: pTa/papillary urothelial neoplasm of low malignant potential (n=19; 28.4%), Primary tumor (pT) in situ (n=4; 6%), pT1 (n=7; 10.4%), and pT≥2 (n=7; 10.48%). Mean AHNAK2 levels were higher in bladder cancer patients 49.08 pg/mL (standard deviation=114.91) compared to controls 5.28 pg/mL (standard deviation=6.65), P < .05). Significant differences were noted between non-invasive bladder cancer (n=23; mean=7.14 pg/mL; standard deviation=7.26) and invasive bladder cancer (n=14; mean=117.99 pg/mL; standard deviation=168.08) and between non-muscle invasive bladder cancer (mean=23.19 pg/mL; standard deviation=66.93) and muscle-invasive bladder cancer (mean=160.05 pg/mL; standard deviation=199.65) (P < .001). The result of the assays was given as follows: sensitivity: 64.19%, specificity: 66.67%, positive predictive value: 22.07%, negative predictive value: 92.37%, area under curve: 0.695, and 95% CI: 0.57-0.82. Conclusion: AHNAK2 protein could be used as bladder cancer surveillance biomarker. The inclusion of AHNAK2 levels in stratification nomograms might reduce the number of unnecessary cystoscopies. Cite this article as: Komina S, Petrusevska G, Jovanovic R, et al. AHNAK2 urinary protein expression as potential biomarker for bladder cancer detection: A pilot study. Turk J Urol. 2022;48(6):423-430.Keywords
This publication has 26 references indexed in Scilit:
- Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New ChallengesCurrent Medicinal Chemistry, 2019
- Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based CytologyMolecular & Cellular Proteomics, 2018
- An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancerWorld Journal of Urology, 2018
- Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysisOncotarget, 2017
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder TumoursEuropean Urology, 2016
- ImmunoCyt test compared to cytology in the diagnosis of bladder cancer: A meta-analysisOncology Letters, 2016
- Urinary Biomarkers for Diagnosis of Bladder CancerAnnals of Internal Medicine, 2015
- Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysisCanadian Urological Association Journal, 2014
- Evaluation of urovysion and cytology for bladder cancer detectionCancer Cytopathology, 2013
- Differences Between Local and Review Urinary Cytology in Diagnosis of Bladder Cancer. An Interobserver Multicenter AnalysisEuropean Urology, 2002